5,300 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Bought by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,300 shares of the biopharmaceutical company’s stock, valued at approximately $196,000.

Several other institutional investors have also added to or reduced their stakes in the business. US Bancorp DE increased its stake in shares of Halozyme Therapeutics by 43.8% during the first quarter. US Bancorp DE now owns 12,663 shares of the biopharmaceutical company’s stock valued at $506,000 after buying an additional 3,859 shares during the period. HighTower Advisors LLC grew its holdings in Halozyme Therapeutics by 7.3% in the first quarter. HighTower Advisors LLC now owns 11,952 shares of the biopharmaceutical company’s stock worth $477,000 after purchasing an additional 812 shares during the last quarter. PNC Financial Services Group Inc. increased its position in shares of Halozyme Therapeutics by 31.9% during the first quarter. PNC Financial Services Group Inc. now owns 16,826 shares of the biopharmaceutical company’s stock worth $671,000 after purchasing an additional 4,066 shares in the last quarter. Natixis Advisors L.P. lifted its holdings in shares of Halozyme Therapeutics by 14.9% during the 1st quarter. Natixis Advisors L.P. now owns 30,219 shares of the biopharmaceutical company’s stock valued at $1,205,000 after purchasing an additional 3,928 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in shares of Halozyme Therapeutics by 10.5% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 51,597 shares of the biopharmaceutical company’s stock worth $2,058,000 after purchasing an additional 4,920 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Down 0.6 %

Shares of NASDAQ:HALO opened at $37.81 on Friday. Halozyme Therapeutics, Inc. has a 52-week low of $29.85 and a 52-week high of $45.00. The stock has a market cap of $4.80 billion, a P/E ratio of 17.92, a PEG ratio of 0.44 and a beta of 1.25. The business has a fifty day moving average of $39.50 and a two-hundred day moving average of $37.76. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 3.45 earnings per share for the current year.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total value of $416,400.00. Following the sale, the senior vice president now owns 156,558 shares in the company, valued at $6,519,075.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 30,000 shares of company stock worth $1,196,800. Company insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

HALO has been the topic of several recent research reports. TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. Benchmark reiterated a “buy” rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday. Morgan Stanley cut their price objective on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating for the company in a research report on Tuesday, December 26th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $72.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.29.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.